But if it seems as if everyone you know has gotten sick this winter (or still is), you’re not wrong: It’s been a tough season for other respiratory viruses.
H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...